Related Experiment Videos
Clinicopathological Profiles and Prognosis of Postoperative HER2-Mutant Non-Small Cell Lung Cancer: A Real-World
Guangjian Yang1, Linyan Tian2, Xiaoyong Tang1
1Department of Respiratory Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, 250117, China.
Background/Introduction:
Patients with non-small cell lung cancer (NSCLC) harboring HER2 mutations remain at high risk of recurrence, even following radical resection for early-stage disease. Currently, there is a paucity of research investigating the clinicopathological characteristics and disease-free survival (DFS) outcomes of this specific postoperative population.
Methods:
This retrospective study investigated the clinicopathological and molecular characteristics of 77 patients with surgically resected HER2-mutant NSCLC. HER2 mutation status was identified via next-generation sequencing (NGS).
Results:
HER2 exon 20 insertions were the most prevalent variant in this cohort. Overall, 76.6% of patients exhibited invasive adenocarcinoma phenotypes. Histopathological examination revealed highly invasive papillary and micropapillary components in 51.9% and 45.5% of patients, respectively. The median DFS was 17.0 months (95% CI, 11.4-22.5), with significant variation across disease stages (P = 0.004). The cumulative number of high-risk recurrence factors (0, 1-3, >3) was significantly associated with DFS (median, 29.3 vs. 14.2 vs. 7.1 months; P = 0.045). However, PD-L1 expression status, TP53 alterations, and histological phenotypes demonstrated no significant impact on DFS. Among the entire cohort, 80.5% of patients experienced postoperative recurrence, with the lung being the most frequent site of metastasis.
Conclusion:
HER2-mutant NSCLC constitutes a distinct subtype characterized by unique clinicopathological and molecular features. For postoperative patients presenting with advanced disease or an increased burden of high-risk recurrence factors, more aggressive therapeutic strategies should be considered.
